Oleg Nodelman

Guest · 2 tracked predictions

Resolved only

0 resolved · 2 total

Right	0
Wrong	0

Small sample size (2 predictions): treat this accuracy figure as anecdotal, not statistically meaningful.

Predictions

All-In's Best Ideas Pitch Competition: 4 Investors Present Their Top Trades Live Too Early Fri, 12 Jun 2026 01:25:00 +0000 · 00:32:38

Actis Oncology will report initial clinical trial data for both of its lead programs (Nectin-4 and B7H3) in 2027, with Nectin-4 data arriving as early as Q1.

“Actis started clinical trials last year and is publicly guided to initial clinical data in both of these lead programs in 2027 with Nectton 4 coming as early as Q1.” View on YouTube

Explanation

This prediction concerns 2027 clinical trial data readouts that have not yet occurred.

All-In's Best Ideas Pitch Competition: 4 Investors Present Their Top Trades Live Too Early Fri, 12 Jun 2026 01:25:00 +0000 · 00:34:32

Actis Oncology could be worth $10 billion, or about $200 per share, if even one of its two lead drug programs makes it to market.

“We think Actis could be worth 10 billion or $200 per share if even one of their programs makes it to market.” View on YouTube

Explanation

This prediction is conditional on future clinical and market success that has not yet been determined.